Overview
Creating a promising solution that addresses unmet needs for patients is the main goal for any innovative life sciences startup. However, navigating deal conversations and securing financing to bring it to life can be a significant challenge – and is often compared to building a plane mid-flight!
Making decisions, particularly when it comes to financing, often involves making trade-offs that may benefit the immediate future but introduce risks in the long run. These trade-offs can sometimes limit your choices and force you to make decisions that you would have handled differently if you had the flexibility to focus on the long-term goals of the company. Some examples of these trade-offs include managing early investor dilution, dealing with complex cap tables and down rounds, while also striving to pursue ambitious R&D plans to increase your chances of success. Additionally, there is the challenge of balancing team renumeration, hiring, and retention to ensure you have an ace team that can help realize your vision. All of this requires careful consideration and is certainly no easy task.
Join Johnson & Johnson Innovation - JLABS Singapore for a special event where you can gain valuable knowledge from industry experts who will share their insights on the intricacies of financing a startup. During this panel, you will have the opportunity to learn from real-world experiences in deal-making and forming collaborations. Don't miss out on this opportunity – RSVP to reserve your seat!
Schedule
Date: 20 Jun 2024, Thursday
Time: 3:30 PM - 6:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: HUONE Singapore (Theatre Room), 3D River Valley Rd, #03-01 Block D, Singapore, 179023
Speakers
Speaker's Profile:
Miemie Strydom, Director New Business Development, Johnson & Johnson Innovative Medicine, Asia Pacific
Miemie is an active healthcare investor/advisor and business development executive with more than 15 years industry experience in both advisory capacity (Deutsche Bank, IQVIA), and “in-house” as member of management teams (DaVita, Reckitt Benckiser, Indivior, Hummingbird Bioscience, Johnson & Johnson). As Director of New Business Development at Johnson & Johnson Innovative Medicine, Asia Pacific, she owns commercial viability assessments and end-to-end deal execution for external investment cases in Immunology and Haematology for Asia Pacific
Speaker's Profile:
Chik Wai Chiew, CEO and Executive Director, Heritas Capital Management
Wai Chiew has over 25 years of experience in global investment management and strategic business development, having been active in leading various companies on transformational growth strategies, fundraising and M&A. In his previous roles at Temasek and other funds, he has led and managed investments across multiple industries and geographies, deploying capital for institutions as well as multiple family offices. Wai Chiew has also been active in championing technology commercialisation and backing deep tech start-ups, having led A*Star’s technology commercialisation and also co-founded a technology incubator. Since joining Heritas Capital, Wai Chiew has expanded its private equity investment portfolio and initiated venture capital, fund-of-funds, and impact-first investments into healthcare, education, environment, and technology sectors globally.
Speaker's Profile:
Vishal Doshi, CEO, AUM Biosciences
Vishal Doshi is the CEO of AUM Biosciences, an award winning clinical-stage oncology company focused on advancing a pipeline of precision therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. A pharmacist and medicinal chemist by training, his strong scientific background comes from breast cancer research in Aromatase inhibitors. Vishal is an experienced senior management with extensive experience in fund raising, clinical development, commercialization and deal structuring of over a $6 Billion. He has a prior track record of successfully exiting a global virtual pharma model including a ~$145M PE deal with Eisai resulting in 3 major blockbusters, such as Lenvima, Eribulin, and ONTAK. He is also a Key Opinion Leader with the KHIDI which is part of the Ministry of Health in South Korea. He has also been nominated as a Young Global Leader by the World Economic Forum.
Speaker's Profile:
Ronne Yeo, Head, Venture Relations, JLABS Singapore, Johnson & Johnson
As Head of Venture Relations, Ronne manages JLABS’ community of investors in life sciences and healthcare to support the success of JLABS residents. His role is to connect high potential companies and their founders with the right funding partner by establishing and strengthening JLABS’ relationship with investors as well as mentoring and coaching its residents. Ronne was formerly a biotech investor with a track record of creating and growing biotech companies. He joined EVX Ventures in 2016 and was promoted to Managing Director, where he evaluated investment opportunities and oversaw its biotech portfolio. During his tenure, Ronne co-founded two biotech companies in the cell and gene therapy space where he took on roles such as fund raising, R&D, business development and strategy. Both companies collectively raised over USD40 million to date.
